| Literature DB >> 30209196 |
Jason Weatherald1,2,3,4,5,6, Athénaïs Boucly1,2,3,6, David Launay7,8,9,10, Vincent Cottin11,12, Grégoire Prévot13, Delphine Bourlier14, Claire Dauphin15, Ari Chaouat16,17,18, Laurent Savale1,2,3, Xavier Jaïs1,2,3, Mitja Jevnikar1,2,3, Julie Traclet11,12, Pascal De Groote18, Gérald Simonneau1,2,3, Eric Hachulla7,8,9,10, Luc Mouthon19,20, David Montani1,2,3, Marc Humbert1,2,3,6, Olivier Sitbon21,2,3,6.
Abstract
The prognostic importance of follow-up haemodynamics and the validity of multidimensional risk assessment are not well established for systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH).We assessed incident SSc-PAH patients to determine the association between clinical and haemodynamic variables at baseline and first follow-up right heart catheterisation (RHC) with transplant-free survival. RHC variables included cardiac index, stroke volume index (SVI), pulmonary arterial compliance and pulmonary vascular resistance. Risk assessment was performed according to the number of low-risk criteria: functional class I or II, 6-min walking distance (6MWD) >440 m, right atrial pressure <8 mmHg and cardiac index ≥2.5 L·min-1·m-2Transplant-free survival from diagnosis (n=513) was 87%, 55% and 35% at 1, 3 and 5 years, respectively. At baseline, 6MWD was the only independent predictor. A follow-up RHC was available for 353 patients (median interval 4.6 months, interquartile range 3.9-6.4 months). The 6MWD, functional class, cardiac index, SVI, pulmonary arterial compliance and pulmonary vascular resistance were independently associated with transplant-free survival at follow-up, with SVI performing better than other haemodynamic variables. 1-year outcomes were better with increasing number of low-risk criteria at baseline (area under the curve (AUC) 0.63, 95% CI 0.56-0.69) and at first follow-up (AUC 0.71, 95% CI 0.64-0.78).Follow-up haemodynamics and multidimensional risk assessment had greater prognostic significance than at baseline in SSc-PAH.Entities:
Mesh:
Year: 2018 PMID: 30209196 DOI: 10.1183/13993003.00678-2018
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671